Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Satoshi ITANO"'
Autor:
Shigeo Shimose, Hideki Iwamoto, Tomotake Shirono, Masatoshi Tanaka, Takashi Niizeki, Masahiko Kajiwara, Satoshi Itano, Yoichi Yano, Satoru Matsugaki, Etsuko Moriyama, Yu Noda, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12325-12335 (2023)
Abstract Background and Aims We aimed to validate the predictive factors for tumor response and the prognostic impact of conversion therapy aimed at cancer‐ and drug‐free states in patients with unresectable hepatocellular carcinoma (u‐HCC) und
Externí odkaz:
https://doaj.org/article/26571559f9b244bc907903ba1baffeb9
Autor:
Shigeo Shimose, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Taizo Yamaguchi, Satoshi Itano, Hideya Suga, Takashi Niizeki, Etsuko Moriyama, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Masahito Nakano, Takumi Kawaguchi, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract This study aimed to investigate the clinical characteristics of patients with unresectable hepatocellular carcinoma (HCC), who were eligible for sequential systemic therapy. We evaluated 365 patients with HCC who underwent systemic therapy a
Externí odkaz:
https://doaj.org/article/a8c7a028541d4aafa780bbde3d8cc0b9
Autor:
Shigeo Shimose, Atsushi Hiraoka, Masahito Nakano, Hideki Iwamoto, Masatoshi Tanaka, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Kei Ogata, Masahiko Kajiwara, Satoshi Itano, Yoshinori Yokokura, Taizo Yamaguchi, Hiroshi Kawano, Norito Matsukuma, Hideya Suga, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Takumi Kawaguchi, Hironori Koga, Takuji Torimura
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8530-8541 (2021)
Abstract Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafeni
Externí odkaz:
https://doaj.org/article/0894e9642c0c4631b38c4aa5d3985b9c
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0266707 (2022)
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis, as the resectability rate is low due to its diagnosis at a late/advanced stage. Moreover, most patients with resected ICC eventually relapse. Hepatic arterial infusion chemotherapy (HAIC) ha
Externí odkaz:
https://doaj.org/article/af9162f42a2e49ef8739fc5f0c9a0f27
Publikováno v:
Oncology. 100:278-289
Introduction: Although many treatment options are available for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A, those for patients with CP class B remain limited. We aimed to assess the safety and efficacy of hepati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e6ebe1b7b0cc687dbef870b519ce454
https://doi.org/10.1159/000523703
https://doi.org/10.1159/000523703
Autor:
Masahiko Kajiwara, Hironori Koga, Takumi Kawaguchi, Taizo Yamaguchi, Hideya Suga, Yu Noda, Shusuke Okamura, Masatoshi Tanaka, Atsushi Hiraoka, Takaaki Tanaka, Takuji Torimura, Tomotake Shirono, Naoki Kamachi, Hiroshi Kawano, Masahito Nakano, Takashi Niizeki, Satoshi Itano, Shigeo Shimose, Kazunori Noguchi, Yoshinori Yokokura, Hajime Aino, Kei Ogata, Hideki Iwamoto, Norito Matsukuma
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8530-8541 (2021)
Cancer Medicine
Cancer Medicine
Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69fca81c2c710227e89f771d0cd26df5
https://doi.org/10.1002/cam4.4367
https://doi.org/10.1002/cam4.4367
Autor:
Shigeo Shimose, Hideki Iwamoto, Masatoshi Tanaka, Takashi Niizeki, Masahiko Kajiwara, Satoshi Itano, Etsuko Moriyama, Tomotake Shirono, Yu Noda, Naoki Kamachi, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Publikováno v:
Cancers; Volume 14; Issue 17; Pages: 4284
This study aimed to evaluate the correlation between adverse events (AEs) and overall survival (OS) in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab (atezo/beva). This was a multicenter study in which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daf3cb6d687957ca94c9c1df363e9cec
https://pubmed.ncbi.nlm.nih.gov/36077816
https://pubmed.ncbi.nlm.nih.gov/36077816
Publikováno v:
PloS one. 17(4)
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis, as the resectability rate is low due to its diagnosis at a late/advanced stage. Moreover, most patients with resected ICC eventually relapse. Hepatic arterial infusion chemotherapy (HAIC) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1653d7e8f6aefaa51a313860f1ca7b16
https://pubmed.ncbi.nlm.nih.gov/35452492
https://pubmed.ncbi.nlm.nih.gov/35452492
Autor:
Osamu Itano, Hironori Koga, Hiroyuki Suzuki, Takuji Torimura, Satoshi Itano, Takashi Niizeki, Shigeo Shimose, Masatsugu Ishii, Akira Kajiwara, Taizo Yamaguchi, Hideki Iwamoto, Tomotake Shirono
Publikováno v:
Japanese journal of radiology. 40(3)
PURPOSE An indwelling arterial access system via the brachial artery, System-i, has been previously reported. We have modified the technique for the femoral artery approach. This study aimed to evaluate the feasibility and safety of the modified Syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b3e113e54bbf33e09ab6e569afd10dc
https://pubmed.ncbi.nlm.nih.gov/34699022
https://pubmed.ncbi.nlm.nih.gov/34699022
Autor:
Hideki, Iwamoto, Takashi, Niizeki, Hiroaki, Nagamatsu, Kazuomi, Ueshima, Takako, Nomura, Teiji, Kuzuya, Kazuhiro, Kasai, Yohei, Kooka, Atsushi, Hiraoka, Rie, Sugimoto, Takehiro, Yonezawa, Akio, Ishihara, Akihiro, Deguchi, Hirotaka, Arai, Shigeo, Shimose, Tomotake, Shirono, Masahito, Nakano, Shusuke, Okamura, Yu, Noda, Naoki, Kamachi, Miwa, Sakai, Hiroyuki, Suzuki, Hajime, Aino, Norito, Matsukuma, Satoru, Matsugaki, Kei, Ogata, Yoichi, Yano, Takato, Ueno, Masahiko, Kajiwara, Satoshi, Itano, Kunitaka, Fukuizumi, Hiroshi, Kawano, Kazunori, Noguchi, Masatoshi, Tanaka, Taizo, Yamaguchi, Ryoko, Kuromatsu, Atsushi, Kawaguchi, Hironori, Koga, Takuji, Torimura, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan
Publikováno v:
Cancers
Cancers, Vol 13, Iss 646, p 646 (2021)
Volume 13
Issue 4
Cancers, Vol 13, Iss 646, p 646 (2021)
Volume 13
Issue 4
BACKROUND: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with molecular targeted agents such as sorafenib. We investigated whether New-FP (fine-powder cisplatin and 5-fluorouracil), a hepatic arterial infusion chemothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3f1483325e31a608b20b62e39c0d540
https://pubmed.ncbi.nlm.nih.gov/33562793
https://pubmed.ncbi.nlm.nih.gov/33562793